Abstract:Brain metastases (BMs) are common in patients with small cell lung cancer(SCLC) and are usually fatal. The purpose of this analysis is to evaluate the outcomes of SCLC patients with BMs and explore the prognostic factors. Pathological diagnosis of SCLC patients with radiologically confirmed BMs were enrolled except those who received surgery of primary lesion. Overall Survival(OS) was calculated from the date of diagnosis of BMs to the date of death from any cause, or the last follow-up. OS was estimated by the Kaplan-Meier method. Univariate and multivariate analyses were performed by the log-rank and Cox’s proportional hazard model test, respectively. From Jan 2011 to Oct 2014, 224 patients were eligible for the study. The median follow-up time was 14 months (range,1-77). For the entire cohort, median OS was 9 months (95% CI, 7.6-10.4), 1- and 2-year OS rate were 31.2% and 7.7%, respectively. As expected, the OS of patients with oligmetastatic BMs (≤3) turned out to be significantly better compared to the survival of patients with non-oligmetastatic BM s(>3) (10 months vs 7 months, P<0.05). Similarly, median OS of patients with initial brain metastatic presentation was 11 months (95% CI, 9.4-12.6) while OS of patients with brain metastatic development during follow-up was 7 months (95% CI, 5.7-8.3), the difference was statistically significant (P=0.021). In addition, patients received radiation to brain or chemotherapy after diagnosis of BMs also had a significantly better survival rate (P<0.001). Multivariate analyses revealed sex, radiation to brain, number of BMs and chemotherapy after diagnosis of BMs were relevant parameters in predicting outcome of SCLC patients with BMs.Tabled 1Prognostic factorPatients(n)Univariate analysis(P)Multivariate analysis(P)Sex(male/female)199/250.0110.036Age(<70/≥70)198/260.951PS(0-1/2)204/200.562Thoracic radiotherapy(yes/no)81/1430.606Smoking status(never smoker /smoker)54/1700.0390.903Diagnosis of BMs (initial metastatic presentation/ metastatic development during follow-up97/1270.0210.136Symptomatic BMs(yes/no)64/1600.136Hemoglobin at diagnosis of BMs(normal/100-120g/L/80-100g/L)144/65/150.0010.083Radiation to brain(yes/no)157/670.0000.000RPA(I/II/III)40/170/140.0440.123GPA (0-1/1.5-2.5/3/3.5-4)35/138/32/190.265Number of BMs (oligmetastatic BMs/ non-oligmetastatic BMs)138/860.0260.017Volume of BMs(<337mm3/338-1592mm3/1593-11099 mm3/>11100 mm3)54/58/55/570.757Chemotherapy after diagnosis of BMs(yes/no)172/520.0000.000 Open table in a new tab In our investigated population, median OS of SCLC patients with BMs was 9 months. Therapy after diagnosis of BMs(radiation to brain or chemotherapy) could improve clinical outcomes. Meanwhile, sex and number of BMs were implicated to have an impact on survival, these may provide stratification factors in predicting prognosis in future.

Favorable prognosis of breast cancer brain metastases patients with limited intracranial and extracranial metastatic lesions

Factors Prognostic for Brain Metastases from Colorectal Cancer: A Single-Center Experience in China.

Risk Factors of Brain Metastasis and Prognosis in HER2-Positive Breast Cancer: A Single-Institution Retrospective Analysis from China

Whole Brain Radiotherapy-Based Combined Modality Treatment of Brain Metastases from Non-Small Cell Lung Cancer: A Retrospective Analysis of Prognostic Factors

Prognostic Factors and Multidisciplinary Treatment Modalities for Brain Metastases from Colorectal Cancer: Analysis of 93 Patients.

The Infratentorial Localization of Brain Metastases May Correlate with Specific Clinical Characteristics and Portend Worse Outcomes Based on Voxel-Wise Mapping

Cystic Brain Metastasis is Associated with Poor Prognosis in Patients with Advanced Breast Cancer.

Multimodal Therapy is a Better Choice for Patients with Brain Metastasis from Cervical Cancer

Prognosis and Survival for 214 Lung Cancer Patients with Brain Metastases

Development of graded prognostic assessment for breast Cancer brain metastasis incorporating extracranial metastatic features: a retrospective analysis of 284 patients

An Analysis of Clinical Features and Survival for Brain Metastases in Different Subtypes of Breast Cancer

New insights into HER2-low breast cancer brain metastasis: A retrospective analysis

Incidence, Pattern and Prognosis of Brain Metastases in Patients with Metastatic Triple Negative Breast Cancer

Prognostic predictors for breast cancer patients with brain metastasis after radiotherapy

Survival Benefit from Surgical Resection in Lung Cancer Patients with Brain Metastases: a Single-Center, Propensity-Matched Analysis Cohort Study

Brain metastasis from non-small cell lung cancer: management and prognosis of primary lung tumor resection

Predicting survival after brain metastases in patients with bladder cancer

Real-world Analysis of Clinicopathological Characteristics, Survival Rates, and Prognostic Factors in Patients with Melanoma Brain Metastases in China

Novel models by machine learning to predict prognosis of breast cancer brain metastases

PUB085 Outcomes of Small Cell Lung Cancer Patients with Brain Metastases: Prognostic Factors Based on an Analysis of 225 Cases

Clinical characteristics and survival and prognostic factors analysis for patients with melanoma brain metastases